Drug Profile
BI 1808
Alternative Names: anti-TNFRS antibody - BioInvent International; BI-1808Latest Information Update: 11 Dec 2023
Price :
$50
*
At a glance
- Originator BioInvent International
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Regulatory T lymphocyte inhibitors; Type II tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cutaneous T-cell lymphoma; Solid tumours
Most Recent Events
- 03 Nov 2023 Efficacy and adverse events data from a phase I/IIa trial in Solid tumors released by BioInvent International
- 21 Jun 2023 Interim efficacy and adverse events data from a phase I/II trial in Cutaneous T-cell lymphoma and Solid tumours released by BioInvent Therapeutic
- 06 Sep 2022 Interim efficacy and adverse events data from a phase I/II trial in Cutaneous T-cell lymphoma and Solid tumours released by BioInvent Therapeutic